Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Hodgkins”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00739141
What this trial is testing

Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

Who this might be right for
LeukemiaMyelodysplastic SyndromeNon-Hodgkins Lymphoma+2 more
Memorial Sloan Kettering Cancer Center 86
Large-scale testing (Phase 3)Study completedNCT01996865
What this trial is testing

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 503
Not applicableStudy completedNCT00301301
What this trial is testing

A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Who this might be right for
Non-Hodgkins Lymphoma
Royal Marsden NHS Foundation Trust 39
Large-scale testing (Phase 3)UnknownNCT00463463
What this trial is testing

Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Soroka University Medical Center
Not applicableWithdrawnNCT00498667
What this trial is testing

The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma

Who this might be right for
Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse
Rambam Health Care Campus
Testing effectiveness (Phase 2)Study completedNCT00193479
What this trial is testing

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkins Lymphoma
SCRI Development Innovations, LLC 51
Testing effectiveness (Phase 2)Study completedNCT00421395
What this trial is testing

Safety Study of NHL With 90Y-hLL2 IgG

Who this might be right for
NHLB-cell NHLNon-Hodgkins Lymphoma
Gilead Sciences 59
Testing effectiveness (Phase 2)Ended earlyNCT01078922
What this trial is testing

Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

Who this might be right for
Non-Hodgkin Lymphomas
Oncology Specialists, S.C. 11
Testing effectiveness (Phase 2)Study completedNCT00802113
What this trial is testing

Autologous and Allogeneic Transplant for Relapsed Lymphoma

Who this might be right for
Non-Hodgkin's LymphomaHodgkins Disease
Columbia University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03533283
What this trial is testing

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkins Lymphoma
Hoffmann-La Roche 211
Testing effectiveness (Phase 2)Study completedNCT00193466
What this trial is testing

Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who this might be right for
Non-Hodgkins Lymphoma
SCRI Development Innovations, LLC 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04661007
What this trial is testing

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Who this might be right for
Non Hodgkins LymphomaDiffuse Large B-cell Lymphoma
Incyte Biosciences Japan GK 72
Early research (Phase 1)Study completedNCT00443976
What this trial is testing

Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkins LymphomaUnspecified Adult Solid Tumor, Protocol Specific
NCIC Clinical Trials Group 35
Early research (Phase 1)Study completedNCT00807677
What this trial is testing

Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous Leukemia+9 more
Millennium Pharmaceuticals, Inc. 31
Testing effectiveness (Phase 2)Study completedNCT00038545
What this trial is testing

A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center 25
Early research (Phase 1)Ended earlyNCT03465540
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Who this might be right for
Multiple MyelomaAcute Myeloid LeukemiaNon-Hodgkins Lymphoma+4 more
Amgen 24
Testing effectiveness (Phase 2)Ended earlyNCT01622556
What this trial is testing

Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies

Who this might be right for
Hematologic Malignancies
University of Virginia 6
Large-scale testing (Phase 3)Looking for participantsNCT07202052
What this trial is testing

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Who this might be right for
MyelomaNon-Hodgkin's LymphomaLeukemia
Monash University 900
Testing effectiveness (Phase 2)Study completedNCT00665314
What this trial is testing

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

Who this might be right for
LymphomaNon Hodgkin's LymphomaHodgkin's Disease+1 more
Genzyme, a Sanofi Company 5
Testing effectiveness (Phase 2)Ended earlyNCT00100737
What this trial is testing

Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Non-Hodgkin Lymphoma
Chiron Corporation 300
Next Page